Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Tadafumi Asaoka

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112163643. Sources: OpenAlex.

Their work

Papers
60 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 11 papers · 2018: 6 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 6 papers · 2024: 11 papers · 2025: 6 papers · 2026: 5 papers

Papers 50 of 60

  1. Relationship Between Radiographic and Pathological Portal Vein-Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparati… Co-author DOI 10.1002/wjs.70395↗
  2. A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarc… Co-author DOI 10.1007/s00595-026-03481-z↗
  3. Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA. Co-author DOI 10.1038/s41598-026-48779-7↗
  4. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Co-author DOI 10.1371/journal.pone.0345459↗
  5. Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment respo… Co-author DOI 10.3892/ijo.2026.5849↗
  6. Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases. Co-author DOI 10.1016/j.suronc.2025.102225↗
  7. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenoca… Co-author DOI 10.1038/s41598-025-23185-7↗
  8. miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential… Co-author DOI 10.1245/s10434-024-16115-w↗
  9. ASO Author Reflections: Potential of Peripheral Plasma Exosomal miRNA: miR-6855-5p Could Predict Radiosensitivity in Patients with Pancreatic Cancer, and Enhan… Co-author DOI 10.1245/s10434-024-16235-3↗
  10. Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17482-8↗
  11. ASO Author Reflections: Efficacy of SOAT1 Inhibitors against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17667-1↗
  12. Removal of gemcitabine-induced senescent cancer cells by targeting glutaminase1 improves the therapeutic effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.34725↗
  13. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  14. Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plus pancreatic ductal adenocarcinoma patie… Co-author DOI 10.1016/j.ejso.2024.108650↗
  15. Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network anal… Co-author DOI 10.1016/j.pan.2024.09.009↗
  16. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer. Co-author DOI 10.1038/s41598-024-60936-4↗
  17. Portal vein wedge resection and patch venoplasty with autologous vein grafts for hepatobiliary-pancreatic cancer. Co-author DOI 10.1186/s40792-024-01823-y↗
  18. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15118-x↗
  19. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Co-author DOI 10.1245/s10434-024-15199-8↗
  20. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Co-author DOI 10.1245/s10434-024-15244-6↗
  21. ASO Author Reflections: A Novel Mechanism of Anticancer Effect of Skeletal Muscle-Derived Irisin in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15349-y↗
  22. MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0310328↗
  23. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-023-04531-w↗
  24. Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival. Co-author DOI 10.1007/s00423-023-03089-8↗
  25. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. Co-author DOI 10.1007/s10147-023-02306-0↗
  26. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma U… Co-author DOI 10.1245/s10434-022-12985-0↗
  27. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancre… Co-author DOI 10.1245/s10434-022-13024-8↗
  28. [A Case Report-A Successful Case of Distal Pancreatectomy with En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Cancer with an Aberrant Right Hepa… First author PMID 36927906↗
  29. Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cnr2.1582↗
  30. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11668-0↗
  31. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11745-4↗
  32. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadj… Co-author DOI 10.1186/s13063-021-05541-w↗
  33. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07927-2↗
  34. A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cmdc.201900324↗
  35. Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2… Co-author DOI 10.1111/cas.13918↗
  36. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. Co-author DOI 10.1007/s00595-018-1674-3↗
  37. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. Co-author DOI 10.1016/j.hbpd.2018.01.004↗
  38. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1159/000475477↗
  39. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Co-author DOI 10.1245/s10434-018-6431-8↗
  40. Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. Co-author DOI 10.3892/ol.2018.8357↗
  41. The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer. Co-author DOI 10.3892/ol.2018.8795↗
  42. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-016-1405-6↗
  43. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Co-author DOI 10.1007/s00595-017-1522-x↗
  44. Prognostic impact of nodal statuses in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2017.01.003↗
  45. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep42339↗
  46. Fatty Acid-Mediated Stromal Reprogramming of Pancreatic Stellate Cells Induces Inflammation and Fibrosis That Fuels Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000943↗
  47. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Co-author DOI 10.1111/cas.13159↗
  48. Two cases of resectable pancreatic cancer diagnosed by open surgical biopsy after endoscopic ultrasound fine-needle aspiration failed to yield diagnosis: case … Co-author DOI 10.1186/s40792-017-0314-2↗
  49. CT Density in the Pancreas is a Promising Imaging Predictor for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-017-5914-3↗
  50. Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis. Co-author DOI 10.1245/s10434-017-6040-y↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 55 shared papers, 2014–2026 · strength 7.10
  2. Yoshifumi Iwagami · 41 shared papers, 2017–2026 · strength 6.29
  3. Daisaku Yamada · 46 shared papers, 2015–2026 · strength 6.27
  4. Hidetoshi Eguchi · 46 shared papers, 2014–2026 · strength 5.52
  5. Yoshito Tomimaru · 30 shared papers, 2014–2026 · strength 4.82
  6. Kazuki Sasaki · 20 shared papers, 2022–2026 · strength 3.72
  7. Hidenori Takahashi · 19 shared papers, 2021–2026 · strength 3.42
  8. Masahiro Tanemura · 25 shared papers, 2017–2026 · strength 3.06
  9. Hirofumi Akita · 17 shared papers, 2019–2026 · strength 2.88
  10. Kunihito Gotoh · 23 shared papers, 2017–2024 · strength 2.02
  11. Yutaka Takeda · 15 shared papers, 2017–2026 · strength 1.59
  12. Shinichiro Hasegawa · 8 shared papers, 2016–2026 · strength 1.28
  13. Hidetoshi Eguchi · 6 shared papers, 2017–2025 · strength 1.14
  14. Masanori Tsujie · 7 shared papers, 2016–2026 · strength 1.01
  15. Hiroki Ueda · 5 shared papers, 2023–2025 · strength 0.96
  16. Masahiko Kubo · 5 shared papers, 2020–2025 · strength 0.89
  17. Naoko Sekiguchi · 3 shared papers, 2025–2026 · strength 0.72
  18. Osakuni Morimoto · 4 shared papers, 2021–2025 · strength 0.65
  19. Manabu Mikamori · 4 shared papers, 2017–2024 · strength 0.61
  20. Kenta Furukawa · 4 shared papers, 2017–2024 · strength 0.60
  21. Hidetoshi Eguchi · 2 shared papers, 2026 · strength 0.52
  22. Yoshiteru Katsura · 2 shared papers, 2026 · strength 0.50
  23. Masaki Mori · 8 shared papers, 2015–2018 · strength 0.45
  24. Tomofumi Ohashi · 4 shared papers, 2014–2024 · strength 0.44
  25. Ryosuke Maki · 2 shared papers, 2025 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.